Krystal Biotech Inc (KRYS)

Payables turnover

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Cost of revenue (ttm)	US$ in thousands	97,854	96,536	95,405	91,643	83,602	75,785	65,603	55,240	47,176	38,941	31,446	26,454	19,970	13,729	12,173	9,050	7,409	6,489	5,716	5,183
Payables	US$ in thousands	5,359	4,132	4,340	4,446	4,109	3,981	5,761	9,229	8,209	8,398	4,757	1,265	1,844	2,105	2,591	1,613	636	1,021	1,252	896
Payables turnover		18.26	23.36	21.98	20.61	20.35	19.04	11.39	5.99	5.75	4.64	6.61	20.91	10.83	6.52	4.70	5.61	11.65	6.36	4.57	5.78

March 31, 2024 calculation

Payables turnover = Cost of revenue (ttm) ÷ Payables
= $97,854K ÷ $5,359K
= 18.26

The payables turnover ratio for Krystal Biotech Inc has varied over the periods under review. The ratio indicates the efficiency with which the company pays its suppliers. A higher payables turnover ratio generally implies that the company is paying its suppliers more quickly.

From Mar 31, 2019, to Dec 31, 2019, the payables turnover ratio ranged between 4.57 and 6.36, showing a relatively stable performance during this period. However, there was a significant increase in the ratio by Mar 31, 2020, reaching 11.65, which suggests that the company was paying its suppliers more frequently.

Subsequently, the payables turnover ratio saw a decline in the following quarters, hitting a low of 4.70 by Jun 30, 2020, and then gradually increasing before peaking at 23.36 by Dec 31, 2023. This significant increase indicates that Krystal Biotech Inc was paying its suppliers at a much faster rate by the end of 2023 compared to previous periods.

Overall, the trend in payables turnover for Krystal Biotech Inc shows fluctuations over the periods analyzed, with the company demonstrating varying levels of efficiency in managing its accounts payable and supplier payments.